Komori
Obic Business Consultants (4733) · InitiativeAdvanced

R&D Focused on ERP and EB Packages for Corporate Customers

First written in FY2016. 25 of 32 entries say "Restated". Latest entry: FY2026.

32entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019-Q3RestatedFY2020-Q1 – FY2021-Q3RestatedFY2025-H1 – FY2026-H12016: 220162017: 420172018: 420182019: 420192020: 420202021: 320212022: 220222023: 420232024: 320242025: 120252026: 12026
Same theme, other companies
Research and development of business-specific IT systems and infrastructure technologiesA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

1 other company's latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「R&D expenses for the fiscal year were ¥4,428 million,」

    R&D expenses amounted to ¥4,428 million, up from ¥3,701 million in the previous fiscal year. Development resources are being concentrated on 奉行 Cloud, 奉行V ERP Cloud, 奉行 Cloud Edge, AI functionality, regulatory compliance and security.
  2. FY2026-H1RestatedAnnual report

    「R&D expenses for the interim accounting period amounted to ¥2,186 million. There were no material changes in the status of the Company's R&D activities during the interim accounting period.」

    The Company recorded ¥2,186 million in R&D expenses but stated that there were no material changes in the status of its R&D activities.
  3. FY2025-H1RestatedAnnual report

    「R&D expenses for the interim accounting period amounted to ¥2,034 million. There were no material changes in the status of the Company's R&D activities during the interim accounting period.」

    The Company recorded ¥2,034 million in R&D expenses and stated that there were no material changes in the status of its R&D activities.
  4. FY2024AdvancedAnnual report

    「R&D expenses for the fiscal year were ¥3,701.157 million, and the main R&D activities were as follows.」

    R&D expenses increased from ¥3,396 million in the previous fiscal year to ¥3,701 million. Development is progressing on 奉行 Cloud, 奉行V ERP Cloud, 奉行 Cloud Edge, regulatory compliance, AI technologies and other areas.
  5. FY2024-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥2.718 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    R&D expenses were reported at ¥2.718 billion for the cumulative third quarter, and the company stated that there were no material changes in the status of its R&D activities.
  6. FY2024-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.750 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    R&D expenses for the cumulative second quarter were ¥1.750 billion, and the company stated that there were no material changes in the status of its R&D activities.
  7. FY2024-Q1RestatedAnnual report

    「The amount spent on R&D activities during the cumulative first quarter was ¥845 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」

    R&D expenses for the first quarter were ¥845 million, and the company stated that there were no material changes in the status of its R&D activities.
  8. FY2023AdvancedAnnual report

    「R&D expenses for the fiscal year were ¥3,396.546 million, and the main R&D activities were as follows.」

    R&D expenses were ¥3.396 billion. Development progressed on OBUGYO V ERP Cloud, OFFICEBANK Cloud, electronic record retention and electronic invoicing compliance, the Help Center, the OBC Cloud Platform and other areas.
  9. FY2023-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥2.583 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    R&D expenses for the cumulative third quarter were ¥2.583 billion, and the company stated that there were no material changes in the status of its R&D activities.
  10. FY2022AdvancedAnnual report

    「R&D expenses for the fiscal year were ¥3,435.760 million,」

    R&D expenses increased from ¥3,023.105 million in the previous fiscal year to ¥3,435.760 million. The company is advancing its focus on development of OBUGYO Cloud, OBUGYO Cloud Edge, OBUGYO Cloud V ERP, regulatory compliance, Framework and other areas.
  11. FY2022-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥2.559 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥2.559 billion for the cumulative third quarter.
  12. FY2022-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.656 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    The company recorded R&D expenses of ¥1.656 billion and stated that there were no material changes in the status of its R&D activities.
  13. FY2021AdvancedAnnual report

    「R&D expenses for the fiscal year were ¥3,023.105 million, and the main R&D activities were as follows.」

    R&D expenses increased from ¥2.933 billion in the previous fiscal year to ¥3.023 billion. The company is advancing its focus on development of OBUGYO Cloud, OBUGYO Cloud Edge, the OBC Cloud Platform, Framework, Microsoft AI and other areas.
  14. FY2021-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥2.317 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    The company stated that there were no material changes in the status of its R&D activities and reported R&D expenses of ¥2.317 billion for the cumulative third quarter.
  15. FY2021-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.514 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥1.514 billion for the cumulative second quarter.
  16. FY2021-Q1RestatedAnnual report

    「The amount spent on R&D activities during the cumulative first quarter was ¥738 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」

    The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥738 million for the cumulative first quarter.
  17. FY2020RestatedAnnual report

    「R&D expenses for the fiscal year were ¥2,933.427 million,」

    The company recorded R&D expenses of ¥2.933 billion and continued to focus R&D on enterprise cloud ERP, Microsoft technologies, SaaS-based integrated cloud platforms, and support services.
  18. FY2020-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥2.172 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    The company reported R&D expenses of ¥2.172 billion for the cumulative third quarter and stated that there were no material changes in the status of its R&D activities.
  19. FY2020-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.413 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥1.413 billion for the cumulative second quarter.
  20. FY2020-Q1RestatedAnnual report

    「The amount spent on R&D activities during the cumulative first quarter was ¥689 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」

    The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥689 million for the first quarter.
  21. FY2019AdvancedAnnual report

    「R&D expenses for the fiscal year were ¥2,912.549 million, and the main R&D activities were as follows.」

    R&D expenses increased from ¥2.453 billion in the previous fiscal year to ¥2.912 billion, while the company continued to focus development on enterprise cloud ERP, Microsoft technologies, SaaS-based integrated cloud platforms and other areas.
  22. FY2019-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥2.030 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    The company reported R&D expenses of ¥2.030 billion for the cumulative third quarter and stated that there were no material changes in the status of its R&D activities.
  23. FY2019-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.325 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    The company reported R&D expenses of ¥1.325 billion for the cumulative second quarter and stated that there were no material changes in the status of its R&D activities.
  24. FY2019-Q1RestatedAnnual report

    「The amount spent on R&D activities during the cumulative first quarter was ¥634 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」

    The company reported R&D expenses of ¥634 million for the first quarter and stated that there were no material changes in the status of its R&D activities.
  25. FY2018RestatedAnnual report

    「R&D expenses for the fiscal year were ¥2.453 billion, and the main R&D activities were as follows.」

    The company continued to focus R&D on ERP and EB packages, business workflows, OBUGYO Cloud Edge, OBUGYO Cloud, Microsoft technologies, and support services. R&D expenses totaled ¥2.453 billion.
  26. FY2018-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥1.819 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    R&D expenses for the cumulative third quarter were ¥1.819 billion, and the company stated that there were no material changes in the status of its R&D activities.
  27. FY2018-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.220 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    R&D expenses for the cumulative second quarter were ¥1.220 billion, and the company stated that there were no material changes in the status of its R&D activities.
  28. FY2018-Q1RestatedAnnual report

    「The amount spent on R&D activities during the cumulative first quarter was ¥614 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」

    The company reported R&D expenses of ¥614 million for the first quarter and stated that there were no material changes in the status of its R&D activities.
  29. FY2017RestatedAnnual report

    「R&D expenses for the fiscal year were ¥2.343 billion, and the main R&D activities were as follows.」

    The company continued to focus R&D on enterprise ERP and EB packages, Microsoft technologies, and support services, with R&D expenses totaling ¥2.343 billion.
  30. FY2017-Q3RestatedAnnual report

    「The amount spent on R&D activities during the cumulative third quarter was ¥1.683 billion. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」

    R&D expenses for the cumulative third quarter were ¥1.683 billion, and the company stated that there were no material changes in the status of its R&D activities.
  31. FY2017-Q2RestatedAnnual report

    「The amount spent on R&D activities during the cumulative second quarter was ¥1.098 billion. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」

    The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥1.098 billion for the cumulative second quarter.
  32. FY2016First statedAnnual report

    「Product development investment continued to focus on the development of ERP and EB packages for enterprises.」

    R&D expenses for the fiscal year were ¥2.234 billion, with priority allocation to ERP and EB packages, Microsoft technologies and support services.
Moved together

"Ample cash and cash equivalents" moved the same way as this thread, in the same document, in 5 of its 32 moves.

555444★123456
  1. ★This thread
  2. 1Ample cash and cash equivalents5×
  3. 2Review of the Executive Compensation Scheme and Alignment with Shareholder Value5×
  4. 3No. 1 in customer satisfaction and support service quality5×
  5. 4Long-Term, Stable Profit Returns4×
  6. 5Trend of Increasing Revenue and Profits4×
  7. 6Expanding revenue and maintaining or improving operating and ordinary profit margins4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Obic Business Consultants's next results are scheduled for 2026-10-27. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.